Octagon Capital Advisors LP Takes Position in Perspective Therapeutics, Inc. $CATX

Octagon Capital Advisors LP bought a new stake in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 791,555 shares of the company’s stock, valued at approximately $3,301,000. Perspective Therapeutics makes up about 0.4% of Octagon Capital Advisors LP’s investment portfolio, making the stock its 27th biggest holding.

Several other large investors also recently bought and sold shares of CATX. Aigen Investment Management LP bought a new position in Perspective Therapeutics during the fourth quarter valued at $28,000. Russell Investments Group Ltd. grew its stake in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $31,000. AXQ Capital LP increased its holdings in shares of Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $35,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

NYSEAMERICAN CATX opened at $2.91 on Monday. The company’s 50-day moving average price is $3.31 and its 200-day moving average price is $3.90. Perspective Therapeutics, Inc. has a 12 month low of $1.96 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. As a group, equities research analysts expect that Perspective Therapeutics, Inc. will post -1.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

CATX has been the subject of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $12.62.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.